Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: Is there evidence for a withdrawal syndrome?

European Urology

Volumn 65, Issue 2, 2014, Pages 504-505

  Azad, Arun A ^a   Eigl, Bernhard J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CASTRATION RESISTANT PROSTATE CANCER; DRUG WITHDRAWAL; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; KALLIKREINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 84891829537     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.035     Document Type: Letter

References (5)

1. J.A. Witjes A case of abiraterone acetate withdrawal Eur Urol 64 2013 517 518
2. O. Caffo, A. Palermo, and A. Veccia et al. Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer Urology 82 2013 1090 1093
3. L. Albiges, E. Auclin, and B. Rousseau et al. Is there a withdrawal syndrome with abiraterone acetate (AA) [abstract 89]? J Clin Oncol 31 suppl 6 2013
4. G. Attard, A.H. Reid, and T.A. Yap et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
5. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 2000 703 706